There is an odd anomaly in British medical research that deserves wider professional and public discussion than it has yet received. If a volunteer for nontherapeutic research suffers as a direct result of such participation, then provided the research is initiated and/or carried out on behalf of the pharmaceutical industry the volunteer has a right under the Association of the British Pharmaceutical Industry (ABPI) guidelines to be compensated speedily and without any need to prove fault -only evidence of causation is required (1). If on the other hand the research is non-pharmaceutical, or not carried out on behalf of or in co-operation with the pharmaceutical industry, then the volunteer has no such right -it is a matter either of proof of negligence or of 'ex-gratia
There is an odd anomaly in British medical research that deserves wider professional and public discussion than it has yet received. If a volunteer for nontherapeutic research suffers as a direct result of such participation, then provided the research is initiated and/or carried out on behalf of the pharmaceutical industry the volunteer has a right under the Association of the British Pharmaceutical Industry (ABPI) guidelines to be compensated speedily and without any need to prove fault -only evidence of causation is required (1) . If on the other hand the research is non-pharmaceutical, or not carried out on behalf of or in co-operation with the pharmaceutical industry, then the volunteer has no such right -it is a matter either of proof of negligence or of 'ex-gratia payment' at the discretion of the government, via the National Health Service (NHS) and the Department of Health (DH), or Commission advice so far as it applies to the government, though they point out that private sector companies sponsoring research -mostly pharmaceutical companies -'are usually able to ensure that effective provision is made to compensate any reseach subject whose health may be affected' (4). Whatever the arrangements for compensation are, the DH guidelines make it quite clear that research subjects, whether patients or volunteers, must be told about them in advance: 'Volunteers must therefore be told in advance of all known risks and be made aware that there could also be unforeseen risks and of the possible difficulties in obtaining compensation'.
The outcome is that not only does an effective double standard continue, but also that healthy volunteers must be told that the NHS is unable to commit itself to standards for compensation that the medical profession itself believes should apply.
What might be the justification of such a policy? Well it certainly respects the autonomy of research subjects. And in requiring explanation of the risks of harm, known and unknown, the policy is doubtless helping to protect potential research subjects from undertaking anything they might perceive to be too harmful to themselves -though since the 'rules' ofnontherapeutic research are that risks higher than minimal are unacceptable, the actual harm prevented by such a policy (as distinct from its contribution to respect for volunteers' autonomy or self-determination) is likely to be minimal too. Nonetheless it seems quite likely that more people will be put off from volunteering by the new policy, if Is the problem one of resources? So far as nontherapeutic medical research is concerned the answer must surely be no -for the additional cost of providing even a commercially obtained institutional insurance cover against harm caused by participation in nontherapeutic research is likely to be insignificant in comparison with the government's total research budget. The more likely worry at the Department of Health is that if the principle is conceded for nontherapeutic research, it will be difficult to draw the line. The notorious difficulty of distinguishing between therapeutic and non-therapeutic components of medical research in clinical projects where elements of both are involved will lead, it may be argued, to claims for no fault compensation for any harm caused by participation in medical research, including therapeutic research. Thus patients entered for a trial of standard versus new therapy who suffer a standard drug side-effect will claim compensation and the costs of the scheme will become prohibitive. Nor need the slide stop there, for if patients accidentally suffering as a result of a treatment given during research are to be given no-fault compensation then so too should patients who sustain accidental but non-negligent harm as a result of ordinary, non-research, treatment. Soon the flood-gates are open to exceedingly expensive no-fault compensation for any non-negligent harm, including every undesired side-effect caused by any medical treatment; so better not to start down that road, concludes this line of argument.
In a world with unlimited resources it would of course be nice to compensate everyone who was harmed in any way, from any cause. In the real world of severe limitation of resources a clear moral distinction has to be drawn between being accidentally harmed in the pursuit of one's own interests and being accidentally harmed in the altruistic pursuit of benefit for others. Most 
